Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Headlines
    3. >UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug
    Headlines

    UK's Drug-Cost Watchdog Recommends Use of Gsk Unit's Hiv Prevention Drug

    Published by Global Banking & Finance Review®

    Posted on October 16, 2025

    2 min read

    Last updated: January 21, 2026

    Add as preferred source on Google
    UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug - Headlines news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:recommendationsNHShealthcare

    Quick Summary

    NICE approves GSK's Apretude for HIV prevention, allowing NHS access in England and Wales. The drug offers an alternative to oral medications.

    UK's NICE Endorses ViiV Healthcare's HIV Prevention Drug Apretude

    (Reuters) -The UK's drugs cost-effectiveness watchdog has given a positive recommendation for ViiV Healthcare's HIV drug, enabling access to the preventive medicine via the state health system in England and Wales, the GSK unit said on Friday.

    The country's drug regulator had approved ViiV's injection, Apretude, last year for prevention of HIV-1 in adults and young people who weigh at least 35 kilograms and are at high risk of acquiring the infection.

    A positive recommendation from the National Institute for Health and Care Excellence, or NICE, solidifies the final guidance related to Apretude for National Health Service, ViiV said.

    It also allows the drug to be routinely funded and enables access through NHS. Pending any appeals, the drug will be available to eligible people in Wales within two months and in England within three months.

    Such preventative treatments, medically called pre-exposure prophylaxis or PrEP, are used to reduce the risk of acquiring HIV.

    Apretude provides an alternative for people who cannot, or prefer not to, take oral HIV-prevention medication. It won U.S. approval in late 2021 and in Europe in 2023, and generated 279 million pounds ($374.95 million) in global sales last year.

    The drug competes with U.S. drugmaker Gilead's oral daily pills Truvada and Descovy along with long-acting injectable drug Yeztugo.

    ViiV's drug can be given every two months, compared with Gilead's Yeztugo, which is given every six months. GSK is exploring a long acting version of Apretude that could potentially be dosed every four months or more.

    ($1 = 0.7441 pounds)

    (Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)

    Key Takeaways

    • •NICE endorses GSK's Apretude for HIV prevention.
    • •Apretude is available via NHS in England and Wales.
    • •The drug offers an alternative to oral HIV prevention meds.
    • •Apretude competes with Gilead's Truvada and Descovy.
    • •GSK explores a longer-acting version of Apretude.

    Frequently Asked Questions about UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug

    1What is HIV?

    HIV, or Human Immunodeficiency Virus, is a virus that attacks the immune system, making it difficult for the body to fight infections and diseases.

    More from Headlines

    Explore more articles in the Headlines category

    Image for Russia says it supplies fuel to Cuba as humanitarian aid
    Russia Says It Supplies Fuel to Cuba as Humanitarian Aid
    Image for Iranian strikes pose ‘existential threat’, Gulf states tell UN
    Iranian Strikes Pose ‘existential Threat’, Gulf States Tell UN
    Image for Russia says it remains in contact with US on Ukraine settlement
    Russia Says It Remains in Contact With US on Ukraine Settlement
    Image for Putin allies Lukashenko and Kim meet in North Korea
    Putin Allies Lukashenko and Kim Meet in North Korea
    Image for Denmark's Frederiksen faces tough coalition talks to remain prime minister
    Denmark's Frederiksen Faces Tough Coalition Talks to Remain Prime Minister
    Image for UK police arrest two men over arson attack on Jewish community ambulances
    UK Police Arrest Two Men Over Arson Attack on Jewish Community Ambulances
    Image for Cricket-Bairstow joins Livingstone in criticising level of care in England set-up
    Cricket-Bairstow Joins Livingstone in Criticising Level of Care in England Set-Up
    Image for Mullally to be installed as first female Archbishop of Canterbury
    Mullally to Be Installed as First Female Archbishop of Canterbury
    Image for Cyprus seeks new security deal for UK bases, Telegraph reports
    Cyprus Seeks New Security Deal for UK Bases, Telegraph Reports
    Image for British army veteran completes record 100km Land Rover pull
    British Army Veteran Completes Record 100km Land Rover Pull
    Image for Pope Leo laments that Iran war 'getting worse and worse'
    Pope Leo Laments That Iran War 'getting Worse and Worse'
    Image for Denmark's left-wing bloc leads election but lacks majority, exit polls show
    Denmark's Left-Wing Bloc Leads Election but Lacks Majority, Exit Polls Show
    View All Headlines Posts
    Previous Headlines PostSinger Sam Fender Wins Mercury Prize for Album 'People Watching'
    Next Headlines PostTrump, Merck KGaA Announce Deal to Cut Some Ivf Drug Prices